Roche and Molecular Partners enter into alliance

Partnership will combine novel biologics (DARPins) with Roche drug-conjugate technology

05-Dec-2013

Roche and Molecular Partners AG announced that they have entered  into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners’ DARPin® biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

DARPin-drug conjugates would be an exciting new class of drugs offering the potential of enhanced efficacy with substantial patient benefit over existing therapies.

“We are excited about this collaboration as the DARPin platform is truly complementary to our internal capabilities in the large molecule space,” Sylke Poehling, Head of Large Molecule Research at Roche commented. “In the field of drug conjugates, we have identified an excellent opportunity to combine our expertise with the leading company in non-antibody scaffold technology to develop transformative cancer medicines.”

 

Facts, background information, dossiers
  • Roche
  • Molecular Partners
  • cancer
More about Roche
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE